Domiciliary oxygen for interstitial lung disease
- PMID: 11687030
- PMCID: PMC8406521
- DOI: 10.1002/14651858.CD002883
Domiciliary oxygen for interstitial lung disease
Abstract
Background: Retrospective survival data have suggested poor effectiveness of oxygen therapy in patients with interstitial lung disease (ILD).
Objectives: To determine the effect of domiciliary oxygen therapy on survival and quality of life in patients with a diagnosis of ILD and hypoxaemia.
Search strategy: Randomized Controlled Trials (RCTs) were identified using the Cochrane Airways Group register and the search terms: (home OR domiciliary AND oxygen AND (Interstitial lung disease OR ILD OR pulmonary fibrosis OR IPF)).
Selection criteria: Any randomized controlled trial (RCT) in adult patients with hypoxaemia and ILD that compared long term domiciliary or home oxygen therapy with a control group.
Data collection and analysis: Only one unpublished RCT was identified.
Main results: Only one trial was identified. Mortality for both the oxygen treated and control groups was approximately 91% after 3 years (Peto odds ratio 0.99, 95% confidence intervals 0.16,6.26). The effect of oxygen therapy on quality of life and physiological parameters was not reported.
Reviewer's conclusions: The assumption that home oxygen therapy has a beneficial survival effect in patients with ILD has not been demonstrated in the single RCT identified.
Conflict of interest statement
None known
Similar articles
-
Domiciliary oxygen for chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2000;(4):CD001744. doi: 10.1002/14651858.CD001744. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2005 Oct 19;(4):CD001744. doi: 10.1002/14651858.CD001744.pub2. PMID: 11034726 Updated.
-
Domiciliary oxygen for chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2005 Oct 19;2005(4):CD001744. doi: 10.1002/14651858.CD001744.pub2. Cochrane Database Syst Rev. 2005. PMID: 16235285 Free PMC article.
-
Domicilary oxygen for chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2000;(2):CD001744. doi: 10.1002/14651858.CD001744. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2000;(4):CD001744. doi: 10.1002/14651858.CD001744. PMID: 10796666 Updated.
-
Cyclophosphamide for connective tissue disease-associated interstitial lung disease.Cochrane Database Syst Rev. 2018 Jan 3;1(1):CD010908. doi: 10.1002/14651858.CD010908.pub2. Cochrane Database Syst Rev. 2018. PMID: 29297205 Free PMC article.
-
Pulmonary rehabilitation for interstitial lung disease.Cochrane Database Syst Rev. 2021 Feb 1;2(2):CD006322. doi: 10.1002/14651858.CD006322.pub4. Cochrane Database Syst Rev. 2021. PMID: 34559419 Free PMC article.
Cited by
-
Long-term oxygen therapy - Supplement, maintenance, or palliative drug?Lung India. 2022 Mar-Apr;39(2):97-99. doi: 10.4103/lungindia.lungindia_74_22. Lung India. 2022. PMID: 35259789 Free PMC article. No abstract available.
-
Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline.Am J Respir Crit Care Med. 2020 Nov 15;202(10):e121-e141. doi: 10.1164/rccm.202009-3608ST. Am J Respir Crit Care Med. 2020. PMID: 33185464 Free PMC article.
-
Protocol for a mixed-methods study of supplemental oxygen in pulmonary fibrosis.BMC Pulm Med. 2014 Nov 1;14:169. doi: 10.1186/1471-2466-14-169. BMC Pulm Med. 2014. PMID: 25361630 Free PMC article. Clinical Trial.
-
Pragmatic randomised controlled trial of a personalised intervention for carers of people requiring home oxygen therapy.Chron Respir Dis. 2020 Jan-Dec;17:1479973119897277. doi: 10.1177/1479973119897277. Chron Respir Dis. 2020. PMID: 31903773 Free PMC article. Clinical Trial.
-
Oxygen therapy for interstitial lung disease: a systematic review.Eur Respir Rev. 2017 Feb 21;26(143):160080. doi: 10.1183/16000617.0080-2016. Print 2017 Jan. Eur Respir Rev. 2017. PMID: 28223395 Free PMC article.
References
References to studies included in this review
Braghiroli 2000 {unpublished data only}
-
- Braghiroli A, Donner CF. A multicentre randomized controlled trial on long term oxygen therapy in pulmonary fibrosis. Personal communication 2000.
References to studies excluded from this review
Polonski 1995 {published data only}
-
- Polonski L, Krzywiecki A, Polonska A, Tendera M, Cwiertka P, Oklek K, et al. Effects of long term oxygen therapy in patients with idiopathic pulmonary fibrosis. I. Effect on the course of the primary disease and on pulmonary circulation. Polskie Archiwum Medycyny Wewnetrznej 1995;94(4):331‐6. - PubMed
-
- Polonski L, Kusnierz B, Krzywiecki A, Polonska A, Tendera M, Oklek K, et al. Effects of long term oxygen therapy in patients with idiopathic pulmonary fibrosis. II. Effect of oxygen therapy on function of heart ventricles. Polskie Archiwum Medycyny Wewnetrznej 1995;94(4):337‐41. - PubMed
Additional references
Braghiroli 1993
-
- Braghiroli A, Ioli F, Spada EL, Vecchio C, Donner CF, Braghiroli A, et al. LTOT in pulmonary fibrosis. Monaldi Archives for Chest Disease 1993;48(5):437‐40. - PubMed
Crockett 1991
-
- Crockett AJ, Alpers JH, Moss JR. Home oxygen therapy: an audit of survival. Australian and New Zealand Journal of Medicine 1991;21(2):217‐21. - PubMed
Donner 1990
-
- Donner CF, Braghiroli A, Ioli F, Zaccaria S. Long‐term oxygen therapy in patients with diagnoses other than COPD. Lung 1990;168(Suppl):776‐81. - PubMed
Reynolds 1998
-
- Reynolds HY. Diagnostic and management strategies for diffuse interstitial lung disease. Chest 1998;113:195‐202. - PubMed
Schulz 1995
-
- Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12. - PubMed
Zielinski 2000
-
- Zielinski J. Long‐term oxygen therapy in conditions other than chronic obstructive pulmonary disease. Respiratory Care 2000;45(2):172‐6. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical